Amylyx Stock Hits Record High With 64% Surge on Positive Trial Data, Launches $350M Offering
On Tuesday, Amylyx Pharmaceuticals (AMLX) shares hit a record high, surging 64%, after announcing positive topline data from its late-stage LUCIDITY trial of avexitide, a once-daily injection for post-bariatric hypoglycemia. The company simultaneously launched a $350 million underwritten public
GateNews·08-18 21:38
